U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C9H13NO2
Molecular Weight 167.205
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of 3-O-METHYLDOPAMINE

SMILES

COC1=C(O)C=CC(CCN)=C1

InChI

InChIKey=DIVQKHQLANKJQO-UHFFFAOYSA-N
InChI=1S/C9H13NO2/c1-12-9-6-7(4-5-10)2-3-8(9)11/h2-3,6,11H,4-5,10H2,1H3

HIDE SMILES / InChI

Description

3-Methoxytyramine (3-MT) is a human trace amine that occurs as a metabolite of the neurotransmitter dopamine. It has been shown to act as an agonist of human TAAR1, and an inhibitor of mitochondrial respiration. 3-MT has garnered research interest for its potential links and implications to Parkinson's disease and other Neurological disorders.

CNS Activity

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
700.0 nM [EC50]
19.6 mM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Primary
Unknown

PubMed

Sample Use Guides

In Vivo Use Guide
Locomotor activity of DAT-KO and WT mice was measured in an Omnitech CCDigiscan. To assess effects of 3-MT in normal and TAAR1-KO mice, the animals were placed in the locomotor activity chamber and 30 min later various doses of 3-MT were administered i.c.v. over 4 minutes. After infusion, animals were put back into experimental chamber and behavior was monitored for 90 min after administration. 3-MT induced significant behavioral activation in DDD mice. Striatal tissue was collected from DDD mice treated with 36 µg of 3-MT 30 minutes after administration was analyzed for ERK activity. 3-MT caused a significant increase in the level of phosphorylated Erk2, thus indicating that certain receptor-mediated processes in striatal cells are affected by this treatment.
Route of Administration: Other
In Vitro Use Guide
Mitochondria were isolated from whole brains of Sprague-Dawley rats. Mitochondria were suspended in 1 mL of incubation buffer containing 0.095MKCl, 0.075Mmannitol,0.025Msucrose, 0.005MKH2PO4, 0.020MTris-HCl, 0.001MEGTA, pH 7.4 (adjusted with KOH) at a final concentration of between 0.40 and 0.80 mg protein/mL. Malate and pyruvate were added to a final concentration of 10 mM. Oxygen consumption was carried out at 30°C in a closed chamber containing a Clark type oxygen electrode connected to a YSI model5300 oxygen monitor. Following a 10-minute incubation, resting conditions (no ADP) were monitored for 5 minutes, followed by the addition of ADP (0.25 mMfinal concentration) and measurement of active respiration. ADP depleted respiration was also monitored. Pre-incubation with the mitochondrial inhibitor 3-Methoxytyramine (3-MT) was carried out for15 min at 30°C prior to addition of ADP. Incubation with 3-MT was carried out in the dark for the first 10 minutes. IC50measurements represent the millimolar concentration of inhibitor required to inhibit 50% malate/pyruvate supported respiration compared with controls containing no inhibitor following a 15-min incubation at 30°C. 3-MT was found to inhibit brain mitochondrial respiration by MAO-dependent and -independent mechanisms. The IC50 of mitochondrial respiratory inhibition for 3-MT was determined to be 19.6 mM.